News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III
Can-Fite BioPharma (CFBI) Reports Financial Results For Six Months Ended June 30, 2015 8/28/2015
Novo Nordisk A/S (NVO) Pulls the Plug on Expanding Victoza for Type 1 Diabetes 8/27/2015
Veloxis Pharmaceuticals A/S (VELO) Announces Financial Results For The First Six Months Of 2015 And Improves The Full Year Outlook 8/27/2015
DelMar Pharmaceuticals To Announce Fiscal 2015 Year-End Financial Results On September 4, 2015 8/27/2015
Symbiomix Completes Enrollment In Second Pivotal Trial Of SYM-1219 For Bacterial Vaginosis, And Receives FDA Fast Track Designation 8/27/2015
PRANA Biotechnology (PRAN) Reports FY15 Financial Results 8/27/2015
Gilead (GILD) Release: Results From The AMBITION Study Of First-Line Treatment With Letairis And Tadalafil In Pulmonary Arterial Hypertension Published In The New England Journal of Medicine 8/27/2015
Lexicon Pharma (LXRX) Announces Telotristat Etiprate Data To Be Presented At European Cancer Congress 8/26/2015
Emisphere Technologies, Inc. (EMIS) Highlights Eligen Licensee Novo Nordisk A/S (NVO)'s Entry Into Phase IIIa Development Of Oral Semaglutide, A Once Daily Oral GLP-1 8/26/2015
Alliance Foundation Trials And Austrian Breast & Colorectal Cancer Study Group Open Largest Global Phase 3 Trial Of Targeted Therapy, IBRANCE (Palbociclib), For Patients With Hormone Receptor–Positive Early Breast Cancer 8/26/2015
Revitalized Exelixis (EXEL) Grabs Breakthrough Tag for Cabozantinib 8/25/2015
SoCal's Vital Therapies (VTL) Tanks as Liver Therapy Fails Phase III Trial 8/25/2015
FDA Grants Orphan Drug Designation For Tocagen Inc.'s Toca 511 & Toca FC, An Investigational Immuno-Oncology Treatment For Glioblastoma 8/25/2015
FDA And European Medicines Agency Accept Regulatory Applications For Boehringer Ingelheim's Gilotrif (afatinib) For Treatment Of Advanced Squamous Cell Carcinoma Of The Lung 8/25/2015
Allergan (AGN) And Gedeon Richter Ltd. (RIG2.F) To Present Data From Cariprazine Trials At European College Of Neuropsychopharmacology (ECNP) Annual Meeting In Amsterdam 8/25/2015
Ascendis Pharma A/S Reports Second Quarter 2015 Financial Results 8/25/2015
CSL Behring Enrolls First Patient In Global Phase II/III Study Of rVIIa-FP For On-Demand Treatment Of Patients With Hemophilia A Or B With Inhibitors 8/25/2015
Amgen (AMGN) To Present New Long-Term Repatha (Evolocumab) Data Analysis At ESC Congress 2015 8/25/2015
Highland Therapeutics Announces Initiation Of Second Pivotal Trial Of HLD-200 In Pediatric ADHD Patients 8/25/2015
NW Bio (NWBO) Temporarily Halts Patient Screening for DCVax-L Brain Cancer Study 8/24/2015
Pfizer (PFE)'s Trumenba Met All Primary Immunogenicity Endpoints in Two Phase III Studies 8/24/2015
Cardiome Pharma Corp. (COM.TO) Expands Partnership With Eddingpharm (Cayman) Inc. To Commercialize AGGRASTAT In China 8/24/2015
Celator Pharmaceuticals, Inc. Appoints Michael R. Dougherty As Executive Chairman Of Board Of Directors 8/24/2015
Esperance Pharmaceuticals, Inc. Announces Strategic Alliance With MD Anderson Cancer Center 8/24/2015
Bristol-Myers Squibb (BMY) And Pfizer (PFE) To Present New Data On Eliquis (apixaban) At The ESC Congress 2015 8/24/2015
Eisai Company (ESALY.PK) Release: FYCOMPA (perampanel) CIII Demonstrates A Significant Reduction In Primary Generalized Tonic-Clonic (PGTC) Seizure Frequency In Phase 3 Trial Of Patients With Epilepsy Age 12 And Older 8/24/2015
Portage Biotech's Biohaven's Lead Drug Candidate Clears FDA Investigational New Drug Application (IND) Review And Clinical Studies To Begin 8/24/2015
Galena Biopharma  (GALE) Announces Independent Data Safety Monitoring Committee Recommends Reduction Of Cardiac Toxicity Monitoring For Neuvax PRESENT Trial 8/24/2015
Collegium (COLL) Publishes Data From Xtampza ER Phase III Clinical Trial In The Journal PAIN 8/24/2015
Halozyme (HALO) Appoints Michael J. Labarre As Chief Scientific Officer 8/24/2015
Exelixis (EXEL) Release: Data From METEOR Pivotal Trial Of Cabozantinib In Advanced Renal Cell Carcinoma Accepted As Late-Breaker Presentation In Presidential Session At European Cancer Congress 2015 8/24/2015
TiGenix Announces Cx601 Meets Primary Endpoint In Pivotal Phase III Trial 8/24/2015
ImmunoCellular Therapeutics, Ltd (IMUC) Issues Letter To Shareholders, Highlighting Progress On Advancing ICT-107 To Phase 3 Registrational Trial 8/21/2015
Macrocure (MCUR) Sinks as CureXcell Flunks Phase III Study 8/20/2015
DelMar Pharmaceuticals Completes $2.6 Million Registered Direct Offering 8/20/2015
PharmaMar Announces License Agreement With Specialised Therapeutics Australia Pty For APLIDIN (plitidepsin) In Oncology 8/20/2015
VBL Therapeutics (VBLX) Announces First Patient Dosed In Pivotal Phase III Trial Of VB-111 In Recurrent Glioblastoma 8/20/2015
BioMarin (BMRN) Receives Rare Pediatric Disease Designation From FDA For Drisapersen For The Potential Treatment Of Duchenne Muscular Dystrophy 8/20/2015
Dipexium Pharmaceuticals (DPRX) Surpasses Treatment Of 50% Of Subjects In Pivotal Phase 3 Clinical Trial 8/20/2015
Charleston Laboratories, Inc. Announces Completion Of A Second Phase 3 Clinical Trial On Its Lead Product, CL-108, And The Appointment Of Dr. Raymond Dionne To Its Scientific Advisory Board 8/20/2015
SELLAS Life Sciences Expands And Strengthens Leadership Team 8/19/2015
LEO Pharma Release: New Study Investigating The Effect Of Low-Molecular-Weight Heparins On The Treatment Of Blood Clots In Cancer Patients 8/19/2015
Intarcia Announces New Top-Line Phase III Results For Investigational Therapy ITCA 650 In Type 2 Diabetes 8/19/2015
Astex Pharmaceuticals (ASTX) Announces Publication Of Key Clinical Data For Guadecitabine (SGI-110) In The Lancet Oncology 8/19/2015
Boehringer Ingelheim Release: CHMP Recommends Label Update For Giotrif With Addition Of Data Demonstrating Overall Survival Benefit For Patients With EGFR Mutation-Positive Lung Cancer 8/19/2015
Palatin Technologies (PTN) Supports FDA's Approval Of The First-Ever Treatment For Female Sexual Dysfunction 8/19/2015
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Published Data Show STIOLTO RESPIMAT Provides Clinically Meaningful Improvements In COPD Health-Related Quality Of Life Measure 8/18/2015
Armetheon Expands Leadership Team, Names Detlef Albrecht, M.D., As Chief Medical Officer 8/18/2015
Tenax Therapeutics (TENX) Announces Nomination Of James Mitchum To Board Of Directors 8/18/2015
Kuros Biosurgery AG Announces The Successful Closing Of A CHF 15 Million Financing Round 8/18/2015
Swedish Orphan Biovitrum Release: Results From B-YOND Study Reinforce Long-Term Clinical Profile Of Alprolix For The Treatment Of Haemophilia B 8/18/2015
Did Merck & Co. (MRK) and NewLink Genetics (NLNK) Just Cure Ebola? 8/17/2015
Mesoblast (MSB.AX) Reports 2015 Financial Year Results And Provides Update On Phase III Chronic Heart Failure Program 8/17/2015
SAGE Therapeutics (SAGE) Announces First Patient Treated In Phase III STATUS Trial Of SAGE-547 In Super-Refractory Status Epilepticus 8/17/2015
Xbiotech Completes Enrollment For Xilonix Phase III Registration Study In Europe 8/17/2015
Chiasma Announces FDA Acceptance For Filing Of New Drug Application For Octreotide Capsules In Acromegaly 8/17/2015
R-PHARM Acquires IXEMPRA (Ixabepilone) From Bristol-Myers Squibb (BMY) And Launches U.S. Commercial Operations 8/17/2015
Clinical Data From Merz Neurosciences’ Phase III Study Of Xeomin® (Incobotulinumtoxina) For Spasticity To Be Published In “Muscle & Nerve” 8/17/2015
Spectrum Pharmaceuticals, Inc. (SPPI) Announces Agreement With FDA On The Special Protocol Assessment (SPA) For The Upcoming Apaziquone Phase 3 Trial In Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) 8/17/2015
Biogen (BIIB) Release: Results From B-YOND Extension Study Reinforce Long-Term Clinical Profile Of ALPROLIX For The Treatment Of Hemophilia B 8/17/2015
Boehringer Ingelheim Release: New Data Show Spiolto Respimat Provides Meaningful Quality Of Life Improvements In COPD 8/17/2015
OncoGenex Pharmaceuticals Inc. (OGXI) Reports Financial Results For Second Quarter 2015 8/14/2015
AEterna Zentaris (AEZS) Second Quarter Financial And Operating Results 8/14/2015
Sophiris Bio Inc. (SPHS) Reports Second Quarter Financial Results 8/14/2015
Evoke Pharma, Inc. Reports Second Quarter 2015 Results 8/14/2015
Dermira Reports Second Quarter 2015 Financial Results And Provides Corporate Update 8/14/2015
Bellerophon Therapeutics (BLPH) Reports 2015 Second Quarter Operational And Financial Results 8/14/2015
Immunomedics, Inc. (IMMU) Announces Conference Call And Webcast For Fourth Quarter And Fiscal Year 2015 Financial Results 8/14/2015
Innocoll, Inc. (INNL) Announces Second Quarter 2015 Financial And Operating Results And Updates Late-Stage Product Portfolio Progress 8/14/2015
Titan Pharmaceuticals (TTP) Reports Second Quarter 2015 Financial Results 8/14/2015
ImmunoCellular Therapeutics, Ltd (IMUC) Reaches Agreement With FDA On Special Protocol Assessment (SPA) For ICT-107 Phase 3 Registrational Trial In Glioblastoma 8/13/2015
Alimera Sciences (ALIM) Signs Exclusive ILUVIEN Distributor For Italy, San Marino And Vatican City 8/13/2015
Neurocrine Biosciences (NBIX) Announces Completion Of Enrollment Into Kinect 3 Tardive Dyskinesia Study 8/13/2015
CrystalGenomics Partners With Dong-A ST For Acelex Commercialization In Korea 8/13/2015
Pfenex (PFNX) Reports Second Quarter 2015 Results And Provides Business Update 8/13/2015
Tokai Pharmaceuticals (TKAI) Reports Second Quarter 2015 Results 8/13/2015
NephroGenex (NRX) Reports Second Quarter 2015 Financial Results 8/13/2015
Eleven Biotherapeutics (EBIO) Reports Second Quarter 2015 Financial Results 8/13/2015
CoLucid Pharma Announces Second Quarter 2015 Results And Corporate Highlights 8/13/2015
Aradigm Corporation (ARDM) Announces Second Quarter 2015 Financial Results 8/13/2015
Argos Therapeutics, Inc. (ARGS) Reports Second Quarter 2015 Financial Results And Operational Highlights 8/13/2015
Collegium (COLL) Reports Second Quarter Financial Results And Provides Corporate Update 8/13/2015
Otonomy (OTIC) Reports Second Quarter 2015 Financial Results And Provides Corporate Update 8/13/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: New Publication Elaborates On TB4's Effects On Dry Eye Syndrome And Other Potential Ophthalmic Disorders 8/12/2015
Celator Pharmaceuticals, Inc. Announces Second Quarter 2015 Financial Results And Business Update 8/12/2015
Axovant (AXON) Reports Financial Results For The First Fiscal Quarter Of 2015 And Provides Corporate Update 8/12/2015
Ardelyx (ARDX) Reports Second Quarter 2015 Financial Results 8/12/2015
Soligenix (SNGX) Announces Recent Highlights and Second Quarter 2015 Financial Results 8/12/2015
RedHill Biopharma Ltd. (RDHL) To Present RHB-104 Phase III Crohn's Program At The International Research Symposium On Crohn's Disease 8/12/2015
Proteon Therapeutics, Inc. (PRTO) Initiates Second Phase III Clinical Study Of Investigational Drug Vonapanitase 8/12/2015
InSite Vision (ISV) Reports Second Quarter 2015 Financial Results 8/12/2015
Eleven Biotherapeutics (EBIO) Announces First Patients Dosed With EBI-005 In Phase 3 Study In Patients With Moderate To Severe Allergic Conjunctivitis 8/12/2015
Exelixis (EXEL) Announces Second Quarter 2015 Financial Results And Provides Corporate Update 8/12/2015
Dyax Corp. (DYAX) Provides Update On DX-2930 Clinical And Commercial Supply Initiatives 8/12/2015
Akebia Therapeutics, Inc. (AKBA) Announces Second Quarter 2015 Financial Results 8/12/2015
Ischemix Elects Peter G. Milner, MD To Board Of Directors 8/12/2015
Theravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results And Provides Business Update 8/12/2015
Zafgen (ZFGN) Reports Second Quarter 2015 Financial Results 8/12/2015
Zosano Reports Second Quarter 2015 Financial Results 8/12/2015
Histogenics Corporation Announces Second Quarter 2015 Financial And Operating Results 8/12/2015
SAGE Therapeutics (SAGE) Announces Second Quarter 2015 Financial Results And Highlights Recent Progress 8/12/2015
ARCA biopharma Announces Second Quarter 2015 Operating Results And Provides Update On Recent Accomplishments 8/12/2015
Halozyme (HALO) Reports Second Quarter 2015 Financial Results 8/11/2015
Alimera Sciences (ALIM) Reports Second Quarter 2015 Financial Results 8/11/2015
Discovery Laboratories (DSCO) Provides Business Update And Reports Second Quarter 2015 Financial Results 8/11/2015
US Army And Helius Medical Technologies Announce Launch Of Phase III Traumatic Brain Injury Clinical Trial 8/11/2015
Ocular Therapeutix (OCUL) Reports Second Quarter 2015 Financial Results 8/11/2015
Puma Biotech (PBYI) Reports Second Quarter 2015 Financial Results 8/11/2015
AEterna Zentaris (AEZS) Announces Data And Safety Monitoring Board Scheduled To Complete Second Interim Analysis Of The ZoptEC Phase 3 Trial In Endometrial Cancer In Early October 8/11/2015
Synergy Pharma Reports Second Quarter And First Half 2015 Financial Results And Business Update 8/11/2015
Trevena, Inc. (TRVN) Reports Second Quarter 2015 Financial Results And Provides A Corporate Update 8/11/2015
Zogenix (ZGNX) Provides Corporate Update And Reports Second Quarter 2015 Financial Results 8/11/2015
Coherus Reports Second Quarter 2015 Financial And Operating Results 8/11/2015
Intec Pharma Ltd. Announces Closing of U.S. Initial Public Offering 8/10/2015
BioDelivery Sciences International (BDSI) Provides Corporate Update And Reports Second Quarter 2015 Financial Results 8/10/2015
Axsome Announces Enrollment Of The First Patient In A Phase III Trial Of AXS-02 For Complex Regional Pain Syndrome (CRPS) 8/10/2015
Celsion Corporation (CLSN) And myTomorrows Expand ThermoDox European Early Access Program To Include Patients With Primary Liver Cancer And Liver Cancer Metastases 8/10/2015
Celsion Corporation (CLSN) Reports Second Quarter 2015 Financial Results And Provides Business Update 8/10/2015
CEL-SCI (CVM) Reports Third Quarter Fiscal Year 2015 Financial Results 8/10/2015
Antares Pharma, Inc. (ATRS) Reports Second Quarter 2015 Operating And Financial Results 8/10/2015
Horizon Pharma (HZNP) Announces Record Second Quarter 2015 Financial Results 8/10/2015
Gamida Cell Achieves Major Regulatory Milestone: FDA And European Medicines Agency Respond Positively to NiCord Phase III Study Design Outline 8/10/2015
AVEO Oncology (AVEO) Reports Second Quarter 2015 Financial Results 8/10/2015
Argos Therapeutics, Inc. (ARGS) Announces Pilot Clinical Trial Of AGS-003 As Neoadjuvant Immunotherapy For Localized Renal Cell Carcinoma 8/10/2015
GlycoMimetics, Inc. (GLYC) Reports Second Quarter 2015 Results 8/7/2015
ImmunoCellular Therapeutics, Ltd (IMUC) Announces Second Quarter 2015 Financial Results 8/7/2015
Lexicon Pharma (LXRX) Reports 2nd Quarter Financial Results, Provides Clinical Pipeline Update 8/7/2015
NephroGenex (NRX) To Host Conference Call And Webcast On Second Quarter 2015 Financial Results On Thursday, August 13, 2015 8/7/2015
bluebird bio (BLUE) Reports Second Quarter 2015 Financial Results And Recent Operational Progress 8/7/2015
Cytori Therapeutics, Inc. (CYTX) Reports Second Quarter 2015 Business and Financial Results 8/7/2015
XBiotech USA (XBIT) Announces Expansion Of Global Phase III Registration Study In Europe Using Xilonix For Treatment Of Metastatic Colorectal Cancer 8/7/2015
Flexion (FLXN) Reports Second-Quarter 2015 Financial Results 8/7/2015
Inotek Pharmaceuticals Corporation Reports Second Quarter 2015 Financial Results And Operational Highlights 8/7/2015
Tesaro, Inc. (TSRO) Announces Second-Quarter 2015 Operating Results 8/7/2015
La Jolla Pharma (LJPC) Announces Second Quarter 2015 Financial Results And Recent Corporate Progress 8/7/2015
TiGenix Obtains FDA's Endorsement Through Special Protocol Assessment For Its Cx601 Phase III Registration Trial In The US 8/7/2015
Galena Biopharma  (GALE) Reports Second Quarter 2015 Financial Results 8/7/2015
Medivation, Inc. (MDVN) Reports Second Quarter 2015 Financial Results 8/7/2015
Esperion Therapeutics (ESPR) Provides ETC-1002 Development Program Update; Reports Second Quarter 2015 Financial Results 8/7/2015
CTI BioPharma Reports Second Quarter 2015 Financial Results 8/7/2015
Spectrum Pharmaceuticals, Inc. (SPPI) Reports Second Quarter 2015 Financial Results And Pipeline Update 8/7/2015
Alnylam (ALNY) Reports Second Quarter 2015 Financial Results And Highlights Recent Period Activities 8/7/2015
Anacor (ANAC) Reports Second Quarter 2015 Financial Results 8/7/2015
Heron (HRTX) Announces Second Quarter 2015 Financial Results And Recent Corporate Progress 8/7/2015
SAGE Therapeutics (SAGE) Receives Special Protocol Assessment For Phase III STATUS Trial Of SAGE-547 In Super-Refractory Status Epilepticus 8/6/2015
TetraPhase Pharmaceuticals (TTPH) Reports Second-Quarter 2015 Financial Results 8/6/2015
Mast Therapeutics (MSTX) To Host Second Quarter 2015 Financial Results And Corporate Update Conference Call 8/6/2015
Orexigen (OREX) And Takeda (TKPYY) Announce An Amended And Restated Collaboration Agreement 8/6/2015
Celsion Corporation (CLSN) Announces Updated Overall Survival Data From HEAT Study Of ThermoDox In Primary Liver Cancer 8/6/2015
CytoDyn Initiates First Clinical Site For Phase III Trial Of PRO 140 8/6/2015
Jazz Pharmaceuticals (JAZZ) Announces Second Quarter 2015 Financial Results 8/6/2015
Nektar Therapeutics (NKTR) Reports Financial Results For The Second Quarter Of 2015 8/6/2015
Nuvo Research Inc. (NRI.TO) Announces 2015 Second Quarter Results 8/6/2015
Orexigen (OREX) Reports Financial And Business Results For The Second Quarter Ended June 30, 2015 8/6/2015
GW Pharma (GWPH) Reports Third Quarter 2015 Financial Results And Operational Progress 8/6/2015
GW Pharma (GWPH) Receives FDA Fast Track And European Medicines Agency Orphan Designations For Intravenous Cannabidiol In The Treatment Of Neonatal Hypoxic-Ischemic Encephalopathy (NHIE) 8/6/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Provides Update On Clinical Trials In U.S., Korea And China 8/6/2015
Opko Health (OPK) Announces Second Quarter Operating And Financial Results 8/6/2015
Orexigen (OREX) Announces Korean Distributorship Agreement with Kwang Dong Pharmaceutical 8/6/2015
Ironwood (IRWD) Provides Second Quarter 2015 Investor Update 8/6/2015
Synta (SNTA) Reports Second Quarter 2015 Financial Results 8/6/2015
Acceleron Pharma Reports Second Quarter 2015 Financial And Operational Results 8/6/2015
Aerie (AERI) To Present At The Canaccord Genuity Growth Conference 8/6/2015
Infinity Pharmaceuticals Inc. (INFI) Provides Company Update And Reports Second Quarter 2015 Financial Results 8/6/2015
Acadia (ACAD) Announces Publication Of Data From Its -015 Open Label Safety Study In Parkinson’s Disease Psychosis In The Journal Of The American Medical Directors Association 8/6/2015
Enrollment Begins In Cytori Therapeutics, Inc. (CYTX) U.S. Phase III/Pivotal Scleroderma Trial 8/6/2015
Intersect ENT Reports Second Quarter 2015 Results 8/6/2015
Ariad (ARIA) Reports Second Quarter 2015 Financial Results And Progress On Strategic Objectives 8/5/2015
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Publication Of Vosaroxin Phase III VALOR Trial Results In The Lancet Oncology 8/5/2015
Vanda Pharmaceuticals, Inc. (VNDA) Release: HETLIOZ (tasimelteon) Phase III SET And RESET Trial Results Published In The Lancet 8/5/2015
Ironwood (IRWD) And Allergan (AGN) Enter Agreement To Co-Promote VIBERZI For Irritable Bowel Syndrome With Diarrhea (IBS-D) In The U.S. 8/5/2015
Ligand (LGND) Reports Second Quarter 2015 Financial Results 8/5/2015
Concert Pharmaceuticals, Inc. (CNCE) Reports Second Quarter 2015 Financial Results And Provides Company Update 8/5/2015
Osiris Therapeutics, Inc. (OSIR) Announces Second Quarter 2015 Financial Results 8/5/2015
22nd Century Group, Inc. Files Second Quarter 2015 Financial Results And Announces Conference Call To Provide Business Update 8/5/2015
Ophthotech Corporation (OPHT) Reports Second Quarter 2015 Financial And Operating Results 8/5/2015
Trimel Pharmaceuticals (TRL.TO) Announces Second Quarter 2015 Financial Results And Highlights 8/5/2015
Acadia (ACAD) Announces Senior Management Appointments In Manufacturing, Quality, Compliance, Access And Reimbursement And Business Development 8/5/2015
bluebird bio (BLUE) Announces Participation At The 2015 Wedbush PacGrow Healthcare Conference 8/5/2015
Delcath Systems (DCTH) Reports 2015 Second Quarter Financial Results 8/5/2015
Rigel (RIGL) Announces Second Quarter 2015 Financial Results 8/5/2015
Antares Pharma, Inc. (ATRS) Announces First Patients Enrolled In QuickShot Testosterone Supplemental Safety Study 8/4/2015
Oasmia's Paclical Does Well in Head to Head Study with Celgene (CELG)'s Abraxane 8/4/2015
Lexicon Pharma (LXRX) Surges as Telotristat Meets Goals in Phase III Study 8/4/2015
Soligenix (SNGX) Receives Orphan Drug Designation From The European Commission (EC) For SGX301 As A Treatment For Cutaneous T-Cell Lymphoma 8/4/2015
International Clinical Steering Committee Announced For Resverlogix (RVX.TO)'s Phase 3 Betonmace Clinical Trial With RVX-208 "Apabetalone" 8/4/2015
Isis Pharma (ISIS) Reports Positive Data from KYNAMRO (mipomersen sodium) FOCUS FH Phase 3 Study In Patients With Severe Heterozygous Familial Hypercholesterolemia 8/4/2015
Versartis, Inc. (VSAR) Reports Second Quarter 2015 Financial Results 8/4/2015
DURECT Corporation (DRRX) Announces Second Quarter 2015 Financial Results And Update Of Programs 8/4/2015
Incyte (INCY) Reports 2015 Second-Quarter Financial Results And Updates Shareholders On Key Clinical Programs 8/4/2015
Derma Sciences, Inc. (DSCI) To Hold Second Quarter Financial Results Conference Call On August 10th 8/4/2015
Regeneron (REGN) Reports Second Quarter 2015 Financial And Operating Results 8/4/2015
Ocular Therapeutix (OCUL) To Report Second Quarter 2015 Financial Results 8/4/2015
CytRx Corporation (CYTR) Reports 2015 Second Quarter Financial Results 8/3/2015
PTC Therapeutics (PTCT) Reports Second Quarter 2015 Financial Results And Provides Corporate Update 8/3/2015
Threshold Pharmaceuticals, Inc. (THLD) Reports Second Quarter 2015 Financial And Operational Results 8/3/2015
ContraVir Pharmaceuticals Enrolls First Patient In Pivotal Phase 3 Study Of FV-100 For Treatment Of Shingles And Shingles-Associated Pain 8/3/2015
Soligenix (SNGX) Enters Into A $10 Million Equity Purchase Agreement 8/3/2015
Shionogi, Inc.'s Naldemedine Meets Endpoints In Phase III Study 8/3/2015
Elite Pharmaceuticals, Inc. (ELI) Completes Enrollment And Dosing For ELI-200 Phase III Efficacy Trial 8/3/2015



//-->